555TiP A first-in-human trial of the integrin beta-6-targeted antibody–drug conjugate, SGN-B6A, in patients with advanced solid tumors

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1077 ◽

2021 ◽

Vol 32 ◽

pp. S613

Author(s):

E. Calvo ◽

A. Hollebecque ◽

A. Dowlati ◽

S.A. Piha-Paul ◽

V. Galvao ◽

...

Keyword(s):

Solid Tumors ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Human Trial ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

28LBA A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors

European Journal of Cancer ◽

10.1016/s0959-8049(16)31946-3 ◽

2015 ◽

Vol 51 ◽

pp. S724 ◽

Cited By ~ 2

Author(s):

A.W. Tolcher ◽

E. Calvo ◽

M.L. Maitland ◽

B. Gibson ◽

D. Xuan ◽

...

Keyword(s):

Solid Tumors ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7 (PTK7), in Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3757 ◽

2021 ◽

pp. clincanres.3757.2020

Author(s):

Michael L. Maitland ◽

Jasgit C Sachdev ◽

Manish R Sharma ◽

Victor Moreno ◽

Valentina Boni ◽

...

Keyword(s):

Tyrosine Kinase ◽

Solid Tumors ◽

Protein Tyrosine Kinase ◽

Human Study ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Protein Tyrosine ◽

Drug Conjugate ◽

Protein Tyrosine Kinase 7 ◽

Antibody Drug

Download Full-text

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors

Investigational New Drugs ◽

10.1007/s10637-020-00960-z ◽

2020 ◽

Vol 38 (6) ◽

pp. 1815-1825 ◽

Cited By ~ 1

Author(s):

Charlotte Lemech ◽

Natasha Woodward ◽

Nancy Chan ◽

Joanne Mortimer ◽

Louie Naumovski ◽

...

Keyword(s):

Solid Tumors ◽

Dose Escalation ◽

Phase 1 ◽

Prolactin Receptor ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Dose Escalation Study ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3284-y ◽

2017 ◽

Vol 79 (5) ◽

pp. 915-922 ◽

Cited By ~ 2

Author(s):

Wijith P. Munasinghe ◽

Rajendar K. Mittapalli ◽

Hong Li ◽

David M. Hoffman ◽

Kyle D. Holen ◽

...

Keyword(s):

Solid Tumors ◽

Qt Interval ◽

Advanced Solid Tumors ◽

Interval Prolongation ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Qt Interval Prolongation ◽

Antibody Drug ◽

Egfr Antibody

Download Full-text

A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.2511 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 2511-2511 ◽

Cited By ~ 15

Author(s):

Carlos Alberto Gomez-Roca ◽

Valentina Boni ◽

Victor Moreno ◽

John Charles Morris ◽

Jean-Pierre Delord ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors

Investigational New Drugs ◽

10.1007/s10637-019-00754-y ◽

2019 ◽

Vol 38 (1) ◽

pp. 120-130 ◽

Cited By ~ 6

Author(s):

Lee S. Rosen ◽

Robert Wesolowski ◽

Raffaele Baffa ◽

Kai-Hsin Liao ◽

Steven Y. Hua ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Dose Escalation Study ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5565 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5565-5565 ◽

Cited By ~ 10

Author(s):

Jasgit C. Sachdev ◽

Michael L. Maitland ◽

Manish Sharma ◽

Victor Moreno ◽

Valentina Boni ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Protein Tyrosine Kinase ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Protein Tyrosine Kinase 7 ◽

Antibody Drug

Download Full-text

620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1133 ◽

2021 ◽

Vol 32 ◽

pp. S657-S659

Author(s):

E. Shenderov ◽

G.H.G. Mallesara ◽

P.J. Wysocki ◽

W. Xu ◽

R. Ramlau ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Preliminary Results ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors

10.1158/1535-7163.targ-19-b057 ◽

2019 ◽

Cited By ~ 1

Author(s):

Jeffrey Clarke ◽

Siu-Chung Chu ◽

Lillian L Siu ◽

Jean-Pascal Machiels ◽

Benjamin Markman ◽

...

Keyword(s):

Solid Tumors ◽

Clinical Activity ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)

European Journal of Cancer ◽

10.1016/s0959-8049(16)32630-2 ◽

2016 ◽

Vol 69 ◽

pp. S14-S15 ◽

Cited By ~ 5

Author(s):

A. Gazzah ◽

N. Stjepanovic ◽

M.H. Ryu ◽

J. Tabernero ◽

J.C. Soria ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Trial ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text